Transcript Présentation PowerPoint

High-dose ARB monotherapy versus ARB/CCB combination
on cardiovascular events in Japanese elderly high-risk
hypertensive patients. The OSCAR trial
Ogawa H, et al. Hypertens Res. 2009;32:575-580.
Patients’ baseline characteristics
Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New
Orleans.
Results
Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.
Summary
• The OSCAR study is the first large clinical trial to investigate
the effect of high-dose ARB versus ARB plus CCB in high-risk
elderly hypertensive patients
• Blood pressure was significantly lower in the ARB plus CCB
group than in the high-dose ARB group.
• There were no significant differences in primary end point rate,
nor any differences in reducing CV events/non CV death
between the groups
• In subgroup of patients with CV disease, primary end point rate
was significantly higher in the high-dose ARB group than ARB
plus CCB group (P=0.0261).
Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.